» Articles » PMID: 39203434

The Potential of Fish Oil Components and Manuka Honey in Tackling Chronic Wound Treatment

Overview
Journal Microorganisms
Specialty Microbiology
Date 2024 Aug 29
PMID 39203434
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic wounds are becoming an increasing burden on healthcare services, as they have extended healing times and are susceptible to infection, with many failing to heal, which can lead ultimately to amputation. Due to the additional rise in antimicrobial resistance and emergence of difficult-to-treat , , , , , and spp. (ESKAPE pathogens), novel treatments will soon be required asides from traditional antibiotics. Many natural substances have been identified as having the potential to aid in both preventing infection and increasing the speed of wound closure processes. Manuka honey is already in some cases used as a topical treatment in the form of ointments, which in conjunction with dressings and fish skin grafts are an existing US Food and Drug Administration-approved treatment option. These existing treatment options indicate that fatty acids from fish oil and manuka honey are well tolerated by the body, and if the active components of the treatments were better understood, they could make valuable additions to topical treatment options. This review considers two prominent natural substances with established manufacturing and global distribution-marine based fatty acids (including their metabolites) and manuka honey-their function as antimicrobials and how they can aid in wound repair, two important aspects leading to resolution of chronic wounds.

References
1.
Serhan C, Chiang N, Dalli J . The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015; 27(3):200-15. PMC: 4515371. DOI: 10.1016/j.smim.2015.03.004. View

2.
Dawaliby R, Trubbia C, Delporte C, Noyon C, Ruysschaert J, Van Antwerpen P . Phosphatidylethanolamine Is a Key Regulator of Membrane Fluidity in Eukaryotic Cells. J Biol Chem. 2015; 291(7):3658-67. PMC: 4751403. DOI: 10.1074/jbc.M115.706523. View

3.
Codagnone M, Cianci E, Lamolinara A, Mari V, Nespoli A, Isopi E . Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Mucosal Immunol. 2017; 11(1):35-49. DOI: 10.1038/mi.2017.36. View

4.
Murali G, Desouza C, Clevenger M, Ramalingam R, Saraswathi V . Differential effects of eicosapentaenoic acid and docosahexaenoic acid in promoting the differentiation of 3T3-L1 preadipocytes. Prostaglandins Leukot Essent Fatty Acids. 2013; 90(1):13-21. DOI: 10.1016/j.plefa.2013.10.002. View

5.
Schwanke R, Marcon R, Bento A, Calixto J . EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. Eur J Pharmacol. 2015; 785:156-164. DOI: 10.1016/j.ejphar.2015.08.050. View